Navigation Links
Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
Date:5/29/2013

Geneva, Switzerland (PRWEB) May 29, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the newly launched SURE CHO-Mplus™ Library to address a broad range of protein production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications to boost the overall expression of therapeutic protein drugs.

Entitled “The Selexis SURE CHO-Mplus™ Library - A Novel and Powerful Advancement in Biologic Protein Expression,” the 60 minute webinar will begin at 4:00 PM CEST | 10:00 AM EDT | 7:00 AM PDT on Wednesday, June 19, 2013.

Registration URL: https://attendee.gotowebinar.com/register/1073373288445877504
Webinar ID: 123-386-987

In this webinar you will learn:

  •     An overview of the SURE CHO-M production cell line
  •     The construction of the SURE CHO-Mplus™ combinatorial library
  •     How to implement the SURE CHO-Mplus™ Library platform to efficiently advance drug discovery and protein production programs
  •     Case studies utilizing the SURE CHO-Mplus™ Library

Who should attend?

  •     Any scientist working with recombinant protein either as a target or as a future drug
  •     Cell line development scientists and researchers
  •     Biologics development scientists
  •     Cellular biochemists

When:
Wednesday, June 19, 2013
4:00 PM CEST | 10:00 AM EDT | 7:00 AM PDT
50 minute presentation
10 minute Q/A

Webinar Abstract:
The Selexis SURE CHO-Mplus™ Library - A Novel and Powerful Advancement in Biologic Protein Expression

With certain recombinant proteins, optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within Selexis’ SURE CHO-Mplus™ Library a variety of cellular pathway components have been modified to address specific bottlenecks, such as aberrant glycosylation, improper protein folding, metabolic or translation issues. The SURE CHO-Mplus™ Library has been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.

About the Speaker:
Pierre-Alain Girod, PhD, Chief Scientific Officer
Dr. Girod joined Selexis in 2006 and was promoted to Chief Scientific Officer in 2007. Dr. Girod studied and received his PhD from the University of Lausanne. Prior to joining Selexis, Dr. Girod worked at the Department of Biology at the University of Lausanne in the field of targeted protein degradation. Earlier in his career, Dr. Girod completed a postdoctoral fellowship at the University of Wisconsin-Madison in the degradation of proteins by the ubiquitin pathway. In 1993 he returned to Switzerland where he discovered a family of genetic sequences involved in the epigenetic regulation of genes. This discovery has subsequently been used to by pharmaceutical and biotechnology companies to boost expression of therapeutic proteins.
Where:
Registration URL: https://attendee.gotowebinar.com/register/1073373288445877504
Webinar ID: 123-386-987

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:

Read the full story at http://www.prweb.com/releases/webinar_therapeutic_drug/cell_line_development/prweb10777507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Institute for Healthcare Advancement will Honor Four for Excellence in Health Literacy at National Conference
2. Advancement In Door Security Combines Delayed Egress And Latch Retraction In One Panic Hardware Device
3. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
4. Joslins Susan Bonner-Weir, Ph.D., named American Association for the Advancement of Science Fellow
5. LaStone Launches Merger with TIR Massage Stone To Further The Advancement of Massage Therapy Education in 2012
6. Silk and cellulose biologically effective for use in stem cell cartilage repair
7. Frequently used biologic agents might cause acute liver injury
8. Men Biologically Programmed to Steer Clear of Friends Wives
9. Dog Study Raises Prospect of Biological Pacemaker for Humans
10. Medicines quality workshop to address standards for microbiological contamination, bioburden control
11. Dr. Daniel Strader of Dallas Designer Smiles Receives Top Reviews as Local Dallas, TX Dentist for Biological Dentistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... ... Will Never Be The Same” is a fictional tale about growing up with the ... the creation of published author, Kim T. Briggs, a self-described “big kid” who has ... and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama skits ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... ability of physical therapist assistants, under direct supervision of a licensed physical therapist, ... physical therapy receives a consultation and treatment plan from a licensed physical therapist ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... an excellent way to ensure moisture measurements are consistently correct. However, regular ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: